Skip to content 
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey. more
| Time Frame | JNJ | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 3.22% | -0.78% | -1.28% |
| 1-Month Return | 4.69% | 0.89% | 1.37% |
| 3-Month Return | 5.44% | 6.29% | 12.01% |
| 6-Month Return | -2.81% | 6.29% | 15.36% |
| 1-Year Return | 0.51% | 12.68% | 23.24% |
| 3-Year Return | 0.82% | 21.13% | 36.17% |
| 5-Year Return | 36.23% | 74.73% | 101.78% |
| 10-Year Return | 100.86% | 182.71% | 236.91% |
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 82.06B | 82.58B | 93.78B | 94.94B | 85.15B | [{"date":"2019-12-31","value":86.43,"profit":true},{"date":"2020-12-31","value":86.98,"profit":true},{"date":"2021-12-31","value":98.77,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.69,"profit":true}] |
| Cost of Revenue | 27.56B | 28.43B | 29.86B | 31.09B | 26.74B | [{"date":"2019-12-31","value":88.64,"profit":true},{"date":"2020-12-31","value":91.44,"profit":true},{"date":"2021-12-31","value":96.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.01,"profit":true}] |
| Gross Profit | 54.50B | 54.16B | 63.92B | 63.85B | 58.41B | [{"date":"2019-12-31","value":85.27,"profit":true},{"date":"2020-12-31","value":84.73,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.9,"profit":true},{"date":"2023-12-31","value":91.38,"profit":true}] |
| Gross Margin | 66.42% | 65.58% | 68.16% | 67.26% | 68.60% | [{"date":"2019-12-31","value":96.82,"profit":true},{"date":"2020-12-31","value":95.6,"profit":true},{"date":"2021-12-31","value":99.37,"profit":true},{"date":"2022-12-31","value":98.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Operating Expenses | 33.53B | 34.24B | 39.37B | 40.15B | 36.56B | [{"date":"2019-12-31","value":83.52,"profit":true},{"date":"2020-12-31","value":85.29,"profit":true},{"date":"2021-12-31","value":98.06,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.06,"profit":true}] |
| Operating Income | 21.01B | 19.82B | 24.42B | 23.92B | 21.85B | [{"date":"2019-12-31","value":86.04,"profit":true},{"date":"2020-12-31","value":81.19,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.95,"profit":true},{"date":"2023-12-31","value":89.5,"profit":true}] |
| Total Non-Operating Income/Expense | (3.64B) | (3.42B) | (1.77B) | (1.98B) | (6.30B) | [{"date":"2019-12-31","value":-364200000000,"profit":false},{"date":"2020-12-31","value":-341700000000,"profit":false},{"date":"2021-12-31","value":-177100000000,"profit":false},{"date":"2022-12-31","value":-197800000000,"profit":false},{"date":"2023-12-31","value":-630200000000,"profit":false}] |
| Pre-Tax Income | 17.33B | 16.50B | 22.78B | 21.73B | 15.06B | [{"date":"2019-12-31","value":76.08,"profit":true},{"date":"2020-12-31","value":72.43,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.39,"profit":true},{"date":"2023-12-31","value":66.13,"profit":true}] |
| Income Taxes | 2.21B | 1.78B | 1.90B | 3.78B | 1.74B | [{"date":"2019-12-31","value":58.38,"profit":true},{"date":"2020-12-31","value":47.12,"profit":true},{"date":"2021-12-31","value":50.16,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":45.88,"profit":true}] |
| Income After Taxes | 15.12B | 14.71B | 20.88B | 17.94B | 13.33B | [{"date":"2019-12-31","value":72.42,"profit":true},{"date":"2020-12-31","value":70.48,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":85.93,"profit":true},{"date":"2023-12-31","value":63.83,"profit":true}] |
| Income From Continuous Operations | 15.12B | 14.71B | 17.80B | 16.37B | 13.33B | [{"date":"2019-12-31","value":84.93,"profit":true},{"date":"2020-12-31","value":82.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.96,"profit":true},{"date":"2023-12-31","value":74.86,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
| Net Income | 15.12B | 14.71B | 20.88B | 17.94B | 35.15B | [{"date":"2019-12-31","value":43.01,"profit":true},{"date":"2020-12-31","value":41.86,"profit":true},{"date":"2021-12-31","value":59.39,"profit":true},{"date":"2022-12-31","value":51.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| EPS (Diluted) | 8.68 | 8.03 | 9.80 | 10.16 | 10.43 | [{"date":"2019-12-31","value":83.22,"profit":true},{"date":"2020-12-31","value":76.99,"profit":true},{"date":"2021-12-31","value":93.96,"profit":true},{"date":"2022-12-31","value":97.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| JNJ | |
|---|---|
| Cash Ratio | 0.54 |
| Current Ratio | 1.17 |
| Quick Ratio | 0.94 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| JNJ | |
|---|---|
| ROA (LTM) | 8.01% |
| ROE (LTM) | 24.24% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| JNJ | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.59 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.41 |
| Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 2.46 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| JNJ | |
|---|---|
| Trailing PE | 23.76 |
| Forward PE | 13.85 |
| P/S (TTM) | 4.17 |
| P/B | 5.17 |
| Price/FCF | 131 |
| EV/R | 4.25 |
| EV/Ebitda | 15.52 |
| PEG | 0.04 |
For the last two years, investors in consumer staples stocks saw every tiny step forward smacked down by two large steps back. Therefore, the 900+-point gain in the Dow Jones Industrial Average ( DJIA ) the week of July 15 was noteworthy. It suggested that the long-awaited “sector rotation” was finally underway. Over the past two years, the dual impact of high inflation and interest rates has affected consumers. As businesses lost their pricing power, it was easier for investors to focus on the fast-growing technology sector. Not surprisingly the market gains have been heavily concentrated in big technology stocks . But the market is forward thinking. And institutional investors are expecting lower interest rates perhaps as early as September. That’s put them on the hunt for stocks and sectors that are undervalued. One likely area is consumer staples. These stocks have been underperforming the market with some trading at or near their 52-week lows. That means there’s an opportunity for many of these stocks to play catch-up as the market continues to broaden out.
The Dow Jones Industrial Index is made up of 30 of the largest, publicly traded companies trading on either the New York Stock Exchange ( NYSE ) or the Nasdaq . These companies are known as blue-chip stocks to buy for their ability to deliver stable, reliable performance no matter what’s going on in the economy. These stocks are part of many institutional portfolios. In fact, if you own a mutual fund like the SPDR S&P 500 ETF (NYSEARCA: SPY ), you own more than one of these blue-chip stocks. However, when choosing individual stocks to own, retail traders and investors may stay away from these stocks in favor of companies that offer stronger growth potential. That was the case in 2023 and has continued in 2024. Investors flocked into tech stocks and particularly artificial intelligence ( AI ) stocks. However, there are signs that the current market rally is likely to expand beyond the Magnificent 7. And with a two-day rally that sent the Dow stocks up over 900 points, it’s likely that investors are looking for blue-chip stocks to buy like the ones listed here.
Market mosaic: Navigating through a mixed performance landscape Today''s stock market presents a vibrant tapestry of performances across various sectors, illustrated vividly in the latest heatmap snapshot. As markets oscillate, understanding sectoral dynamics becomes crucial for informed investment strategies. Technology Sector: A close scrutiny The technology sector shows a divergent performance with Microsoft (MSFT) witnessing a notable decline of 1.80%, suggesting investor caution or profit-taking within the software-infrastructure field. Conversely, Apple (AAPL) sees an upturn by 0.67%, possibly reflecting confidence in consumer electronics. Semiconductor stocks like Nvidia (NVDA) and Intel (INTC) are slightly down, indicating specific stress within this sub-sector. Health and Pharmaceuticals: Booming potential Pharmaceutical giants like Eli Lilly (LLY) have soared, with an impressive increase of 1.98%, signaling strong investor confidence possibly spurred by promising developments or financial results.
HBM Healthcare Investments AG / Key word(s): Quarter Results 19-Jul-2024 / 06:45 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Quarterly profit of CHF 26 million NAV increases by 1.6 percent and share price rises by 5.9 percent Private portfolio companies as value drivers Positive start to the new financial year HBM Healthcare Investments started the new 2024/2025 financial year with a quarterly profit of CHF 26 million. The net asset value per share (NAV) rose by 1.6 percent in the first three months to 30 June 2024, while the share price increased by 5.9 percent. The focus was on positive developments in the portfolio of private companies, which contributed a total of CHF 53 million to the result, while public companies and funds had a negative impact on the result of CHF –14 million and CHF –4 million respectively. Developments in the portfolio of public companies The public companies weighed on the 3-month result by a total of CHF –14 million.
Dividend stocks pay dividends to their shareholders, representing a portion of the company’s profits. Not all companies offer dividends. But those that do allow their board of directors to decide the amount based on the company’s financial health and economic considerations. Dividends are typically paid out in cash on a monthly, quarterly or yearly basis. In the U.S, the vast majority of companies pay dividends on a quarterly basis. To be eligible for a dividend, an individual must be a shareholder of record on a specified date set by the board. Stocks bought on or after the ex-dividend date will not qualify for the current dividend, but may do so in the following period. In the U.S., dividends are paid from the company’s after-tax profits and are taxed as ordinary income by the IRS. This taxation applies to shareholders when they receive dividend payments. The dividend yield, a key metric for investors, is inversely related to the stock’s price. It represents the ratio of the annual dividend payment to the stock’s price.
Johnson & Johnson (NYSE:JNJ) stock rose 0.064% (As on July 18, 11:23:54 AM UTC-4, Source: Google Finance) after the company’s second-quarter profit beat Wall Street… The post Johnson & Johnson (NYSE:JNJ) Beat Wall Street Projections appeared first on FXDailyReport.Com .
With all the superlatives being heaped upon the S&P 500 and the Nasdaq 100 indices as they push higher into record territory, the venerable Dow Jones Industrial Average lags. It is up only 8% year-to-date, less than half the gains of its peers. Yet it is still at a record high. This discrepancy highlights the importance of stocks with stability, such as blue-chip stocks . It might not happen this week or next month or even this year. But as a part of the investing cycle, the stock market will correct and it could fall hard . Investors should be ready. I like to take a two-pronged approach. On the one hand, I keep a lot of powder dry. I build up the cash portion of my portfolio so that when stock prices do fall, even crater, I’m ready to pounce to scoop up good deals. The second prong is to buy blue-chip stocks ahead of a crash. Blue-chip stocks are successful, profitable companies with a long history of growth through all business cycles. Even better, blue-chip stocks more often than not pay a dividend.
Johnson & Johnson (JNJ) share price today is $154.69
Yes, Indians can buy shares of Johnson & Johnson (JNJ) on Vested. To buy Johnson & Johnson from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in JNJ stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Johnson & Johnson (JNJ) via the Vested app. You can start investing in Johnson & Johnson (JNJ) with a minimum investment of $1.
You can invest in shares of Johnson & Johnson (JNJ) via Vested in three simple steps:
The 52-week high price of Johnson & Johnson (JNJ) is $170.63. The 52-week low price of Johnson & Johnson (JNJ) is $141.57.
The price-to-earnings (P/E) ratio of Johnson & Johnson (JNJ) is 10.09
The price-to-book (P/B) ratio of Johnson & Johnson (JNJ) is 5.17
The dividend yield of Johnson & Johnson (JNJ) is 3.28%
The market capitalization of Johnson & Johnson (JNJ) is $371.16B
The stock symbol (or ticker) of Johnson & Johnson is JNJ
Link copied 
